NUCLEOLIN and cancer: AS1411, an unmodified guanosine-rich 26-mer DNA oligonucleotide that specifically binds to nucleolin, is the first aptamer to enter clinical trials for cancer treatment via mechanisms affecting cancer cell growth, proliferation, and survival (Mongelard & Bouvet, 2010).